Renal Cell Carcinoma

During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc

Eric Jonasch, MD, discusses the 3-year follow-up of the LITESPARK-001 trial of belzutifan in patients with clear cell renal cell carcinoma.

Dr Nizar Tannir describes data presented at ASCO 2022 from EVEREST investigating everolimus vs placebo for patients with high-risk disease.

Experts discuss the use of pembrolizumab as an adjuvant therapy in advanced clear cell RCC.

During a Targeted Oncology case-based roundtable event, Randy F. Sweis, MD, discussed with participants their experience with the tolerability of tivozanib for recurrent advanced renal cell carcinoma. This is the first of 2 articles based on this event.

Dr Scott Tykodi explains the scenarios in which he would switch a patient to another regimen without dose reduction first.

The panel discusses which of the four approved combination regimens in advanced clear cell RCC they would choose for higher-risk patients, and the factors that play into the decision.

During a tweet chat, Shifeng S. Mao, MD, PhD and Targeted Oncology Twitter followers discussed the case of 59-year-old woman with clear-cell renal cell carcinoma ad best treatment options for the patient.

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed how to treat a patient with intermediate-risk renal cell carcinoma.

Following the success of immunotherapy-based therapy, investigators continue to explore new approaches for patients in a rapidly evolving field to continue to move the needle toward improved outcomes for patients with kidney cancer.

Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.

Dr Scott Tykodi shares his take on discontinuation of IO-TKI combination regimens because of toxicities.

An expert explains how he assesses a patient’s tolerability of the IO-TKI combination regimens and at what point he discontinues treatment.

During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed with participants their experiences using lenvatinib in treatment of advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Rana McKay, MD, shares advice for community oncologists treating patients with advanced renal cell carcinoma.

Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.

Dr Rana McKay reviews key efficacy data from the COSMIC 313 trial and discusses factors that are considered when choosing between IO-TKI or IO-IO combinations.

Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.

Rana McKay, MD, presents the case of a 73-year-old man with advanced renal cell carcinoma, shares her initial impression, and reviews which factors contribute to a patient’s risk status.

Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.

Shared insight on the data from the COSMIC-313 trial and the potential for first-line triplet regimens in patients with advanced clear cell renal cell carcinoma.

Moshe Ornstein, MD, MA, continues his discussion of I/O-TKI combination regimens by presenting data from the CheckMate 9ER trial.

Moshe Ornstein, MD, MA, shares data from the KEYNOTE-426 clinical trial that set a new standard of care for treatment-naïve metastatic clear cell RCC.

During a case-based roundtable event, Thomas Hutson, DO, PharmD, discussed challenges with treating a 59-year-old woman with clear cell renal cell carcinoma.

Panelists identify second-line treatment options they would consider in advanced clear cell RCC if a patient progresses following first-line therapy.